Blackstone Group buys Cardinal Health unit for $3.3B
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Cardinal Health |
Blackstone Group |
$3.3B sale |
Cardinal Health has struck a deal to sell its pharmaceutical technologies and services business to the Blackstone Group. |
|
MDS |
Molecular Devices |
$615M buyout |
MDS plans to combine Molecular Devices--which makes software and systems for researchers engaged in biochemical testing and cellular analysis--with MDS Sciex. |
|
AstraZeneca |
Argenta |
$521M development deal |
Argenta will work with AstraZeneca on a therapy for chronic obstructive pulmonary disease. |
|
AstraZeneca |
Palatin Technologies |
$310 development deal |
Palatin Technologies is developing obesity drugs. |
|
Hikma |
Ribosepharm |
$45M buyout |
Ribosepharm markets injectable generic oncology drugs. |
|
Health Acquisition Corp. |
PharmAthene |
Merger |
PharmAthene is going public through a merger with Health Acquisition Corp. |
|
PsychoGenics |
Amylin Pharmaceuticals |
Merger |
PsychoGenics and Amylin Pharmaceuticals have formed Psylin Neurosciences, a new company that will focus on the discovery and development of peptide hormones for treatment of psychiatric disorders. |
|
Quotient BioResearch |
HFL |
Acquisition |
Quotient BioResearch announced its launch with the acquisition of HFL, a UK-based firm that provides research and development support to pharmaceutical and biotech companies. |
|
Pfizer |
MediVas |
Development deal |
MediVas has teamed with Pfizer to develop new therapies for eye diseases. The pact will combine MediVas work in polymers with Pfizer's compounds. |